IDO was demonstrated to drive IL-6 production in lung cancer and metastatic breast cancer, while, downstream product of IDO metabolism, kynurenic acid, can potentiate IL-6 production by the aryl hydrocarbon receptor (AHR) [19]. The gene discussed is IDO1; the disease is lung carcinoma.